0001209191-21-056060.txt : 20210914 0001209191-21-056060.hdr.sgml : 20210914 20210914193111 ACCESSION NUMBER: 0001209191-21-056060 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210407 FILED AS OF DATE: 20210914 DATE AS OF CHANGE: 20210914 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Renaud Ronald C JR CENTRAL INDEX KEY: 0001354434 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-38550 FILM NUMBER: 211253774 MAIL ADDRESS: STREET 1: C/O IDENIX PHARMACEUTICALS, INC. STREET 2: 60 HAMPSHIRE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02109 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Translate Bio, Inc. CENTRAL INDEX KEY: 0001693415 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 611807780 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 29 HARTWELL AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 617-945-7361 MAIL ADDRESS: STREET 1: 29 HARTWELL AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 FORMER COMPANY: FORMER CONFORMED NAME: RaNA Therapeutics, Inc. DATE OF NAME CHANGE: 20161228 4/A 1 doc4a.xml FORM 4/A SUBMISSION X0306 4/A 2021-04-07 2021-04-09 0 0001693415 Translate Bio, Inc. TBIO 0001354434 Renaud Ronald C JR C/O TRANSLATE BIO, INC. 29 HARTWELL AVE LEXINGTON MA 02421 1 1 0 0 Chief Executive Officer Common Stock 2021-04-07 4 M 0 9026 7.39 A 503231 D Common Stock 409913 I By Ronald Renaud 2014 Irrevocable Family Trust Common Stock 40909 I By Ronald C. Renaud, Jr. Trust - 2007 Stock Option (right to buy) 7.39 2021-04-07 4 M 0 9026 0.00 D 2027-12-21 Common Stock 9026 1071009 D The original Form 4 filed on April 9, 2021 inadvertently reported the incorrect number of securities beneficially owned following the reported transaction by an additional 90 shares. The original Form 4 filed on April 9, 2021 stated that 503,321 shares were owned after the transaction. The correct number of shares is 503,231. This amendment is being filed solely to correct the number of securities beneficially owned. This option was granted on December 22, 2017. The shares underlying the option vested over four years in equal monthly installments through March 9, 2021. /s/ Paul Burgess, as attorney-in-fact for Ronald C. Renaud, Jr. 2021-09-14